Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering.
Kathryn R MichelsAlyssa SheihSusana A HernandezAlissa H BrandesDon ParrillaBlythe IrwinAnai M PerezHung-An TingChristopher J NicolaiTimothy GervascioSeungjin ShinMark D PankauMason MuhonenJessica FreemanSarah GouldRich GettoRyan P LarsonByoung Y RyuAndrew M ScharenbergAlessandra M SullivanShon GreenPublished in: Journal for immunotherapy of cancer (2023)
These findings demonstrate that UB-VV100 generates functional CAR T cells in vivo, which could expand patient access to CAR T technology in both hematological and solid tumors without the need for ex vivo cell manufacturing.